Delving into the Latest Updates on Travoprost with Synapse

The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.

Start Date05 Jan 2026

Sponsor / Collaborator

Wills Eye Institute

[+1]

NCT07400926

/ RecruitingNot Applicable

Clinical In-use Observational Trial to Evaluate the Updated Inserter for the Travoprost Intracameral Implant 75 mcg

Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)

Start Date17 Dec 2025

Sponsor / Collaborator

Glaukos Corp.

100 Clinical Results associated with Travoprost

Login to view more data

100 Translational Medicine associated with Travoprost

Login to view more data

100 Patents (Medical) associated with Travoprost

Login to view more data

820

Literatures (Medical) associated with Travoprost

01 Apr 2026·Ophthalmology and Therapy

Safety and Feasibility of the Exchange Procedure for the Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension

Article

Author: Katz, L Jay ; Sarkisian, Steven R ; Applegate, David ; Kothe, Angela C ; Navratil, Tomas ; Lehmann, Robert P ; Jones, Jason J ; Berdahl, John P

INTRODUCTION:

We conducted a prospective, single-arm, open-label study to evaluate the feasibility and safety of an exchange procedure for the travoprost intracameral implant.

METHODS:

Adult subjects with open-angle glaucoma or ocular hypertension who had previously received a travoprost intracameral implant were enrolled at 12 sites in the United States and one in the Philippines. Subjects were administered a new travoprost intracameral implant followed by removal of the previous implant ("exchange" procedure). The primary outcome measures were treatment-emergent adverse events, and other ocular safety parameters (i.e., endothelial cell density, visual acuity, slit-lamp biomicroscopy, and visual fields).

RESULTS:

Thirty-three subjects who had received a travoprost intracameral implant for a mean duration of 4.2 years prior were recruited. All subjects were successfully implanted with a new implant, and the previous implant was successfully removed. There were no treatment-related serious adverse events, or severe treatment-related adverse events in the eye that underwent the exchange procedure. No subject required a subsequent explantation.

CONCLUSIONS:

Travoprost intracameral implant demonstrated an acceptable safety profile both during and after the exchange procedure, supporting its re-administration.

CLINICALTRIALS:

gov NCT04615403.

01 Feb 2026·DRUGS & AGING

Implants to Treat Glaucoma: Promising or Not?

Review

Author: Kolko, Miriam ; Cvenkel, Barbara

Glaucoma is one of the leading causes of blindness and its prevalence increases with age. The most common form, primary open-angle glaucoma, is a chronic, slowly progressive optic neuropathy characterised by the loss of retinal ganglion cells and their axons, leading to irreversible visual field loss. Elevated intraocular pressure (IOP) is the only modifiable risk factor for glaucoma. Reducing IOP to a level that is safe for the patient's eye has been shown to slow disease progression. Lowering IOP in open-angle glaucoma is achieved by eye drops, selective laser trabeculoplasty (SLT) and/or surgery. Many patients are treated with IOP-lowering eye drops, which require lifelong continuous instillation. However, as with other chronic, asymptomatic diseases, adherence to glaucoma treatment is poor for various reasons and is associated with faster disease progression. The purpose of this review is to discuss several sustained-release systems that have been investigated to reduce IOP over time, to address barriers to adherence and improve quality of life. Among these, non-invasive drug-eluting delivery systems such as contact lenses, punctal plugs, and conjunctival ocular inserts have not reached the market. Currently, only two intracameral implants have been approved by the Food and Drug Administration for single use due to corneal safety issues. The biodegradable bimatoprost implant releases the drug continuously for 4-6 months, and its effect on IOP may extend for up to 2 years in 25% of patients. The non-biodegradable intracameral implant releases travoprost for 36 months, when it needs to be removed. However, additional data are needed to assess safety following repeated administration, as well as in broader patient populations and in combination with other treatment approaches such as SLT. Several other biodegradable intracameral implants that release prostaglandin analogues are undergoing clinical trials. In the future, intraocular implants containing genetically modified cells that secrete neurotrophic factors may potentially offer an IOP-independent neuroprotective strategy, complementing existing IOP-lowering implants in glaucoma management.

01 Jan 2026·ARQUIVOS BRASILEIROS DE OFTALMOLOGIA

Beyond pressure control: Periorbital impact of prostaglandins vs. laser trabeculoplasty

Article

Author: Lavinsky, Daniel ; Pakter, Marina M ; Leivas, Leonardo ; Almeida, Rafaela C ; Fabris, Marcelo V ; Lindenmayer, Rodrigo L ; Pakter, Helena M ; Lavinsky, Fábio ; Procianoy, Fernando

PURPOSE:

To assess the one-year impact of prostaglandin analog (travoprost) on periorbital appearance and lower eyelid horizontal tension, compared with the contralateral eye treated with Pascal selective laser trabeculoplasty.

METHODS:

This nested case-control study was derived from a non-inferiority randomized clinical trial comparing Pascal selective laser trabeculoplasty efficacy with travoprost in fellow eyes over 12 months. One eye received daily travoprost, while the contralateral eye underwent Pascal selective laser trabeculoplasty. Lower eyelid horizontal tension was measured using a validated digital imaging method, and prostaglandin-associated periorbitopathy signs were graded by masked observers. Statistical analyses included generalized estimating equations and the Mann-Whitney U test for nonparametric data, with p<0.05 considered significant.

RESULTS:

Ten patients met the inclusion criteria for this subanalysis. Travoprost-treated eyes had significantly lower mean lower eyelid distension compared with Pascal selective laser trabeculoplasty-treated eyes (4.32 mm vs. 5.02 mm; mean difference: 0.70 mm; p<0.001). Prostaglandin--associated periorbitopathy scores were significantly higher in the travoprost group, reflecting more pronounced changes in ptosis, periorbital hyperpigmentation, and eyelid retraction.

CONCLUSIONS:

Chronic use of prostaglandin analogs is associated with notable periorbital changes and increased lower eyelid tension, potentially affecting aesthetics and ocular function. Pascal selective laser trabeculoplasty may offer a safer profile for preserving periorbital anatomy while maintaining effective intraocular pressure control. Laser trabeculoplasty should be considered as an initial treatment when appropriate to minimize cosmetic and functional changes from chronic topical therapy.

154

News (Medical) associated with Travoprost

15 May 2026

·www.globenewswire.com

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Amy Ricca, the Company’s new SVP, Head of HR. The awards were made as an inducement material to the recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards granted to Ms. Ricca were effective as of May 11, 2026 and consist of a non-statutory stock option award to purchase up to 75,000 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 25,000 shares of Ocular’s common stock. Ms. Ricca’s stock option award has an exercise price of $9.28 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. The stock option award has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The restricted stock unit awards vest over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The inducement awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program. Follow the Company on its website, LinkedIn, or X. DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & MediaOcular Therapeutix, Inc.Bill SlatteryVice President, Investor Relationsbslattery@ocutx.com

Phase 3Phase 2

15 May 2026

·www.biospace.com

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 15, 2026

BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Amy Ricca, the Company’s new SVP, Head of HR. The awards were made as an inducement material to the recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards granted to Ms. Ricca were effective as of May 11, 2026 and consist of a non-statutory stock option award to purchase up to 75,000 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 25,000 shares of Ocular’s common stock. Ms. Ricca’s stock option award has an exercise price of $9.28 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. The stock option award has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The restricted stock unit awards vest over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The inducement awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan. About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA ® , an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program. Follow the Company on its website, LinkedIn, or X. DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations bslattery@ocutx.com

Phase 3Phase 2

10 May 2026

·www.biospace.com

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 8, 2026

BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to twelve newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of May 4, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 127,650 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 41,550 shares of Ocular’s common stock. The stock option awards have an exercise price of $9.71 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. Each of the stock option awards has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. Each of the restricted stock unit awards vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan. About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA ® , an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program. Follow the Company on its website, LinkedIn, or X. DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations bslattery@ocutx.com

Phase 3Phase 2Drug Approval

100 Deals associated with Travoprost

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01964	Travoprost	S01EE04	DB00287

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	Japan	Novartis Pharmaceuticals Corp.	31 Jul 2007
Glaucoma, Open-Angle	United States	Alcon Pharmaceuticals Ltd.	16 Mar 2001
Ocular Hypertension	United States	Alcon Pharmaceuticals Ltd.	16 Mar 2001

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertension	NDA/BLA	United States	Glaukos Corp.	05 May 2023
Glaucoma-Related Pigment Dispersion Syndrome	Phase 3	-	Alcon Research Ltd.	01 Nov 2011
Glaucoma, Angle-Closure	Phase 3	United States	Alcon Research Ltd.	01 Jan 2000
Glaucoma, Angle-Closure	Phase 3	Australia	Alcon Research Ltd.	01 Jan 2000
Exfoliation Syndrome	Clinical	United States	Alcon Research Ltd.	01 Sep 2003

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06582732 (Pubmed \| Ophthalmol Ther)	Phase 2	Glaucoma, Open-Angle	210	Travoprost Intracameral Implant	ppzuvnhmma(oxykhvhtss) = muejztgyif bjrubypdwh (jigxdfmykj )	Positive	24 Mar 2025
NCT06061718 (Pubmed \| Ther Adv Ophthalmol)	Phase 3	Ophthalmologic surgical procedures	60	Travoprost intracameral implant + Cataract surgery	zsausyiipl(jdptsbwjul) = Study eye adverse events were reported in 8.3% of patients rxpjegvfgs (enqhpwwuvq ) View more	Positive	01 Jan 2025
NCT06582732 (CTgov)	Phase 2	Glaucoma, Open-Angle	210	Travoprost Intracameral Implant exchanged at Month 12 (Cohort 1 (12-month Exchange))	qzmfxocqfd(asamxelvgh) = nljthmwlrr vkfzkyimlw (amshesukxf, 3.02) View more	-	15 Oct 2024
				Travoprost Intracameral Implant exchanged at Month 3 (Cohort 2 (3-month Exchange))	chtcrzrbad(secdoetyez) = pwryrrjbmp gkgpqhkoqt (vfvysnvmuw, 2.50) View more
NCT04360174 (CTgov)	Phase 1	Ocular Hypertension \| Glaucoma, Open-Angle	19	OTX-TIC (OTX-TIC-Cohort 1)	bdofvyduwx = wixwbigllk lmkbsewfdl (ulqqdzcdop, rcovhmgysw - jefczzykba) View more	-	01 Oct 2024
				OTX-TIC (OTX-TIC-Cohort 2)	bdofvyduwx = tkcgkkrzpc lmkbsewfdl (ulqqdzcdop, ggrakmpksd - skohxyielu) View more
NCT03519386 \| NCT03868124 (Pubmed)	Phase 3	Ocular Hypertension \| Glaucoma, Open-Angle	133	Travoprost Intracameral Implant	siizuidhbk(orxeoxxytm) = berncrkhqu rtztxkyoki (utiqfueeyz )	Positive	10 Jul 2024
				Topical Prostaglandin Analog	siizuidhbk(orxeoxxytm) = dcjvxuwwiw rtztxkyoki (utiqfueeyz )
NCT05335122 (GlobeNewswire) Manual	Phase 2	Glaucoma, Open-Angle	-	26 µg of PAXTRAVA	faymnvkwix(raskimavpg) = hymnfsjrjl mbxffxlqow (fkkyposwso )	Positive	06 Apr 2024
				DURYSTA	-
NCT03519386 (Pubmed \| Ophthalmol Ther)	Phase 3	Ocular Hypertension \| Glaucoma, Open-Angle	590	Travoprost intracameral SE-implant	zhrjbdsakj(ifdiwscchh) = yxuoxkxrxo kogvscogff (firmgjucev, < 1.5 mmHg at all six timepoints and < 1 mmHg at three or more timepoints)	Positive	01 Apr 2024
				Travoprost intracameral FE-implant	zhrjbdsakj(ifdiwscchh) = ofqwefqcre kogvscogff (firmgjucev, < 1.5 mmHg at all six timepoints and < 1 mmHg at three or more timepoints)
NCT02754596 (Pubmed \| Drugs)	Phase 2	Ocular Hypertension \| Glaucoma, Open-Angle	-	Fast-eluting implant (FE implant)	ontmcpnmxr(wqjrmrxpjg) = rgbmbzrhbc yvdwezahbu (bnupdbifps )	Positive	01 Jan 2024
				Slow-eluting implant (SE implant)	ontmcpnmxr(wqjrmrxpjg) = tgjptvbehh yvdwezahbu (bnupdbifps )
NCT03519386 \| NCT03868124 (GC-012, FDA) Manual	Phase 3	Glaucoma, Open-Angle \| Ocular Hypertension	868	iDose TR (GC-010)	moahoxktyn(wvrakrelvk) = tuypgtfavu anvjmnmftf (ojyttfyvbe ) View more	Positive	13 Dec 2023
				Timolol (GC-010)	moahoxktyn(wvrakrelvk) = qdltspgngo anvjmnmftf (ojyttfyvbe ) View more
NCT04615403 (CTgov)	Phase 2	Glaucoma, Open-Angle	33	Travoprost	tmzwlacyhp = pxvtryzkdx fgzzrdnhlo (vkiiwkvlwv, thjrfjevgt - zcfadfjwho) View more	-	26 Sep 2023